Evidence map›Paper›PMID 34620874›Full record

ReviewNature reviews. Disease primers2021

Histiocytic disorders.

Kenneth L McClain, Camille Bigenwald, Matthew Collin, Julien Haroche, Rebecca A Marsh, Miriam Merad, Jennifer Picarsic, Karina B Ribeiro, Carl E Allen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Kenneth L McClainTexas Children's Cancer Center, Department of Paediatrics, Baylor College of Medicine, Houston, TX, USA. klmcclai@txch.org.ORCID 0000-0003-0725-6263
Camille BigenwaldDepartment of Oncological Sciences and Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-2714-2087
Matthew CollinHuman Dendritic Cell Lab, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Julien HarocheDepartment of Internal Medicine, Institut E3M French Reference Centre for Histiocytosis, Pitié-Salpȇtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Paris, France.
Rebecca A MarshDivision of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, USA.
Miriam MeradDepartment of Oncological Sciences and Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-4481-7827
Jennifer PicarsicDivision of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0002-3718-6422
Karina B RibeiroFaculdade de Ciȇncias Médicas da Santa Casa de São Paulo, Department of Collective Health, São Paulo, Brazil.
Carl E AllenTexas Children's Cancer Center, Department of Paediatrics, Baylor College of Medicine, Houston, TX, USA.
Baylor College of Medicine · USCincinnati Children's Hospital Medical Center · USIcahn School of Medicine at Mount Sinai · USFaculdade de Ciências Médicas da Santa Casa de São Paulo · BRNewcastle University · GBSorbonne Université · FR

Funding

Tissue ResourceP50CA126752 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Leonid S Metelitsa · 2007 to 2026
$51.4M
ERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0M
The PreVAIL-kIds Common ProtocolR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ALLEN, CARL E, ANNAPRAGADA, ANANTH V · 2023 to 2023
$6.3M
Molecular Epidemiology of Langerhans Cell Histiocytosis: Evaluating the Impact of SMAD6 and Genetic Ancestry on Disease RiskR01CA233719 · NCI · BAYLOR COLLEGE OF MEDICINE · PI HOANG, THANH THIEN, SCHEURER, MICHAEL E. · 2019 to 2023
$3.2M
Cancer Research UK 21025Cancer Research UK C30484/A21025NCI NIH HHS P50 CA126752NCI NIH HHS R01 CA154947NCI NIH HHS R01 CA233719NICHD NIH HHS R33 HD105593
6 · The paper itself

Abstract

The historic term 'histiocytosis' meaning 'tissue cell' is used as a unifying concept for diseases characterized by pathogenic myeloid cells that share histological features with macrophages or dendritic cells. These cells may arise from the embryonic yolk sac, fetal liver or postnatal bone marrow. Prior classification schemes align disease designation with terminal phenotype: for example, Langerhans cell histiocytosis (LCH) shares CD207

Indexed as

Erdheim-Chester DiseaseHistiocytosis, Langerhans-CellHistiocytosis, SinusXanthogranuloma, JuvenileHumansInflammation

Identifiers

PMID34620874
PMCPMC10031765
OpenAlexW4200432403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.